205 related articles for article (PubMed ID: 12354289)
1. Inhibition of tryptophan hydroxylase activity and decreased 5-HT1A receptor binding in a mouse model of Huntington's disease.
Yohrling IV GJ; Jiang GC; DeJohn MM; Robertson DJ; Vrana KE; Cha JH
J Neurochem; 2002 Sep; 82(6):1416-23. PubMed ID: 12354289
[TBL] [Abstract][Full Text] [Related]
2. Striatal phosphodiesterase mRNA and protein levels are reduced in Huntington's disease transgenic mice prior to the onset of motor symptoms.
Hebb AL; Robertson HA; Denovan-Wright EM
Neuroscience; 2004; 123(4):967-81. PubMed ID: 14751289
[TBL] [Abstract][Full Text] [Related]
3. Amyloid formation by mutant huntingtin: threshold, progressivity and recruitment of normal polyglutamine proteins.
Huang CC; Faber PW; Persichetti F; Mittal V; Vonsattel JP; MacDonald ME; Gusella JF
Somat Cell Mol Genet; 1998 Jul; 24(4):217-33. PubMed ID: 10410676
[TBL] [Abstract][Full Text] [Related]
4. Reduced expression of the TrkB receptor in Huntington's disease mouse models and in human brain.
Ginés S; Bosch M; Marco S; Gavaldà N; Díaz-Hernández M; Lucas JJ; Canals JM; Alberch J
Eur J Neurosci; 2006 Feb; 23(3):649-58. PubMed ID: 16487146
[TBL] [Abstract][Full Text] [Related]
5. Interaction of huntingtin fragments with brain membranes--clues to early dysfunction in Huntington's disease.
Suopanki J; Götz C; Lutsch G; Schiller J; Harjes P; Herrmann A; Wanker EE
J Neurochem; 2006 Feb; 96(3):870-84. PubMed ID: 16405500
[TBL] [Abstract][Full Text] [Related]
6. Mutant huntingtin causes context-dependent neurodegeneration in mice with Huntington's disease.
Yu ZX; Li SH; Evans J; Pillarisetti A; Li H; Li XJ
J Neurosci; 2003 Mar; 23(6):2193-202. PubMed ID: 12657678
[TBL] [Abstract][Full Text] [Related]
7. Partial resistance to malonate-induced striatal cell death in transgenic mouse models of Huntington's disease is dependent on age and CAG repeat length.
Hansson O; Castilho RF; Korhonen L; Lindholm D; Bates GP; Brundin P
J Neurochem; 2001 Aug; 78(4):694-703. PubMed ID: 11520890
[TBL] [Abstract][Full Text] [Related]
8. Effects of experimental hypothyroidism on 5-HT1A, 5-HT2A receptors, 5-HT uptake sites and tryptophan hydroxylase activity in mature rat brain1.
Kulikov A; Moreau X; Jeanningros R
Neuroendocrinology; 1999 Jun; 69(6):453-9. PubMed ID: 10364698
[TBL] [Abstract][Full Text] [Related]
9. Compensatory changes in the ubiquitin-proteasome system, brain-derived neurotrophic factor and mitochondrial complex II/III in YAC72 and R6/2 transgenic mice partially model Huntington's disease patients.
Seo H; Kim W; Isacson O
Hum Mol Genet; 2008 Oct; 17(20):3144-53. PubMed ID: 18640989
[TBL] [Abstract][Full Text] [Related]
10. Cardiac dysfunction in the R6/2 mouse model of Huntington's disease.
Mihm MJ; Amann DM; Schanbacher BL; Altschuld RA; Bauer JA; Hoyt KR
Neurobiol Dis; 2007 Feb; 25(2):297-308. PubMed ID: 17126554
[TBL] [Abstract][Full Text] [Related]
11. Impaired basal and running-induced hippocampal neurogenesis coincides with reduced Akt signaling in adult R6/1 HD mice.
Ransome MI; Hannan AJ
Mol Cell Neurosci; 2013 May; 54():93-107. PubMed ID: 23384443
[TBL] [Abstract][Full Text] [Related]
12. Dysfunctional kynurenine pathway metabolism in the R6/2 mouse model of Huntington's disease.
Sathyasaikumar KV; Stachowski EK; Amori L; Guidetti P; Muchowski PJ; Schwarcz R
J Neurochem; 2010 Jun; 113(6):1416-25. PubMed ID: 20236387
[TBL] [Abstract][Full Text] [Related]
13. Expression, pharmacology and functional activity of adenosine A1 receptors in genetic models of Huntington's disease.
Ferrante A; Martire A; Pepponi R; Varani K; Vincenzi F; Ferraro L; Beggiato S; Tebano MT; Popoli P
Neurobiol Dis; 2014 Nov; 71():193-204. PubMed ID: 25132555
[TBL] [Abstract][Full Text] [Related]
14. Dopamine release is severely compromised in the R6/2 mouse model of Huntington's disease.
Johnson MA; Rajan V; Miller CE; Wightman RM
J Neurochem; 2006 May; 97(3):737-46. PubMed ID: 16573654
[TBL] [Abstract][Full Text] [Related]
15. Clioquinol down-regulates mutant huntingtin expression in vitro and mitigates pathology in a Huntington's disease mouse model.
Nguyen T; Hamby A; Massa SM
Proc Natl Acad Sci U S A; 2005 Aug; 102(33):11840-5. PubMed ID: 16087879
[TBL] [Abstract][Full Text] [Related]
16. Mutant huntingtin and glycogen synthase kinase 3-beta accumulate in neuronal lipid rafts of a presymptomatic knock-in mouse model of Huntington's disease.
Valencia A; Reeves PB; Sapp E; Li X; Alexander J; Kegel KB; Chase K; Aronin N; DiFiglia M
J Neurosci Res; 2010 Jan; 88(1):179-90. PubMed ID: 19642201
[TBL] [Abstract][Full Text] [Related]
17. Huntingtin's WW domain partners in Huntington's disease post-mortem brain fulfill genetic criteria for direct involvement in Huntington's disease pathogenesis.
Passani LA; Bedford MT; Faber PW; McGinnis KM; Sharp AH; Gusella JF; Vonsattel JP; MacDonald ME
Hum Mol Genet; 2000 Sep; 9(14):2175-82. PubMed ID: 10958656
[TBL] [Abstract][Full Text] [Related]
18. Corticosterone dysregulation exacerbates disease progression in the R6/2 transgenic mouse model of Huntington's disease.
Dufour BD; McBride JL
Exp Neurol; 2016 Sep; 283(Pt A):308-17. PubMed ID: 27381424
[TBL] [Abstract][Full Text] [Related]
19. Transgenic mice expressing mutated full-length HD cDNA: a paradigm for locomotor changes and selective neuronal loss in Huntington's disease.
Reddy PH; Charles V; Williams M; Miller G; Whetsell WO; Tagle DA
Philos Trans R Soc Lond B Biol Sci; 1999 Jun; 354(1386):1035-45. PubMed ID: 10434303
[TBL] [Abstract][Full Text] [Related]
20. Altered brain neurotransmitter receptors in transgenic mice expressing a portion of an abnormal human huntington disease gene.
Cha JH; Kosinski CM; Kerner JA; Alsdorf SA; Mangiarini L; Davies SW; Penney JB; Bates GP; Young AB
Proc Natl Acad Sci U S A; 1998 May; 95(11):6480-5. PubMed ID: 9600992
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
